Lodastigil, a reversible acetylcholinesterase and butyrylcholinesterase inhibitor as well as an irreversible Monoamine Oxidase Type B (MAO-B) inhibitor, is currently in phase II of clinical trials for its use as an anti-depressant and neuroprotectant agent for the treatment of depression and various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease [28]. This evidence concerns the gene MAOB and major depressive disorder.